Clinical trials: Lymphoid Neoplasms
Chronic Lymphocytic Leukemia
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn if the combination of fludarabine, cyclophosphamide, rituximab, and bevacizumab is effective in treating chronic lymphocytic leukemia in patients who have already been treated…
- Trial name
- NCT00448019
- Testing
- Fludarabine, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
This phase II trial studies how well sapanisertib works in treating patients with acute lymphoblastic leukemia that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory).
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT02484430
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
All
Testing the Re-Engineered Hospital Discharge
The purpose of this study is to determine if the "Re-Engineered Discharge" will decrease rehospitalization rates and adverse events of patients leaving Boston Medical Center.
- Trial name
- NCT00252057
- Testing
- Re-Engineered Hospital Discharge
- Where
- United States
- Volunteers
- 749 people
- Sponsor
- Boston University
Lymphoma, Leukemia
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Primary objective: To determine the safety of adback T- or Natural Killer (NK) cells in patients with lymphoid malignancies receiving allogeneic stem cell transplantation with Campath-IH containing conditioning regimen.
- Trial name
- NCT00536978
- Testing
- ARA-C, BCNU, Campath-1H
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Precursor-B Acute Lymphoblastic Leukemia
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
The goal of this clinical research study is to learn if a chemotherapy combination called augmented Berlin-Frankfurt-Munster (BFM), when also combined with ofatumumab or rituximab, can help to control precursor-B ALL or LL in…
- Conditions
- Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
- Trial name
- NCT02419469
- Testing
- Cytarabine, Daunorubicin, Vincristine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
This study is a means of providing transplantation to those patients who would be a stem cell transplant candidate who do not have an appropriate donor.
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic
- Trial name
- Haplo/Cord (NCT01050946)
- Testing
- Haploidentical/cord transplant
- Volunteers
- 1 people
- Sponsor
- Medical College of Wisconsin
Lymphocytic Leukemia, Chronic
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
This multi-center, single-arm study evaluated the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide in participants with B-cell chronic lymphocytic leukemia (CLL) and favorable somatic status.
- Trial name
- NCT01271010
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 10 sites in Russia
- Volunteers
- 89 people
- Sponsor
- Hoffmann-La Roche
Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB)…
- Conditions
- Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- UCBT (NCT01930162)
- Testing
- HSC835
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia
UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia
The purpose of the study is to investigate the safety of the investigational agent, cirmtuzumab. Cirmtuzumab is a monoclonal antibody drug designed to attach to a protein, called ROR1, on the surface of chronic lymphocytic…
- Trial name
- NCT02222688
- Testing
- cirmtuzumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Thomas Kipps
Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL
To determine the response to the combination of Revlimid (Lenalidomide)+ Vidaza (Azacitidine) in patients with relapsed/refractory CLL and SLL Hypothesis- lenalidomide's activity in combination with azacitidine may further…
- Trial name
- VZCLLPI0146 (NCT01241786)
- Testing
- Revlimid, Azacitidine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Hackensack Meridian Health
Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis.
- Trial name
- NCT03642626
- Testing
- KYMRIAH, YESCARTA, Fludarabine 30mg/m2 4 doses
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Lymphocytic Leukemia
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
This is a multicenter, open-label, single-arm, expanded access treatment study designed to provide obinutuzumab to patients with previously untreated Chronic Lymphocytic Leukemia (CLL) in combination with chlorambucil and to…
- Trial name
- NCT01868893
- Testing
- Obinutuzumab, Chlorambucil
- Where
- 19 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genentech, Inc.
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00453206
- Testing
- allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Wake Forest University Health Sciences
Non-Hodgkin's Lymphoma, Follicular Lymphoma
Study of Repeat Intranodal Injections of Ad-ISF35
This is a Phase II, open label, fixed dose, repeat injection, single institution study. Eligible subjects will receive up to six doses of Ad-ISF35 injected directly into a selected lymph node under ultrasound guidance.
- Conditions
- Non-Hodgkin's Lymphoma, Follicular Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT00942409
- Testing
- ISF35
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Januario Castro, M.D.
Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Stem cell transplant is an important therapeutic option for pediatric patients with relapsed or refractory leukemia. Although, full myeloablative transplants are widely used for patients with acute leukemia, myeloablative…
- Conditions
- Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia, Neoplasm Recurrent
- Trial name
- NCT01041508
- Testing
- Clofarabine, Total Body Irradiation, Stem Cell Transplantation
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm
Design and Testing of a Web-Based Tool for the Improvement of End-of-Life Planning in Patients With Advanced Cancer
This clinical trial examines a web-based tool, in partnership with Peacefully, Inc, designed to improve end-of-life planning among patients with advanced cancers.
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT05564468
- Testing
- Best Practice, Internet-Based Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia
This phase II trial is studying how well dasatinib works in treating patients with unresectable or metastatic squamous cell skin cancer or RAI Stage 0-I chronic lymphocytic leukemia.
- Conditions
- Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
- Trial name
- NCT00563290
- Testing
- dasatinib, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies the efficacy (activity), and tolerability of curcumin and cholecalciferol combination in treating patients with previously untreated stage 0-II chronic lymphocytic leukemia or small lymphocytic…
- Conditions
- Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
- Trial name
- NCT02100423
- Testing
- curcumin, cholecalciferol, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Paolo Caimi, MD
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
This study is being conducted to learn about the effects of SC-PEG, which is a new form of a chemotherapy drug called asparaginase. Asparaginase is used to treat ALL and lymphoblastic lymphoma.
- Trial name
- NCT01574274
- Testing
- SC-PEG, Oncaspar
- Where
- 8 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Small Intestine Cancer
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, and may stimulate the immune system to stop cancer cells from growing.
- Trial name
- NCT00561418
- Testing
- vorinostat, Correlative studies
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.